Collegium Pharmaceutical, Inc. (COLL) 当前追踪市盈率 (P/E) 为 17.2, 前瞻市盈率为 4.4. 追踪盈利收益率为 5.83%, 前瞻盈利收益率 22.62%. PEG 0.01 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $20.60.
本页证实的标准:
SharesGrow 综合评分： 66/100 其中 4/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -4.0 | -0.04 | 2.80 | 220.79 | 6.50% |
| 2017 | -7.5 | 0.21 | 5.37 | 19.62 | - |
| 2018 | -14.4 | 0.28 | 6.16 | 2.01 | - |
| 2019 | -30.3 | 0.38 | 7.87 | 2.32 | - |
| 2020 | 25.8 | -0.06 | 3.70 | 2.22 | - |
| 2021 | 9.1 | 0.06 | 3.22 | 2.36 | - |
| 2022 | -31.4 | 0.23 | 4.03 | 1.69 | - |
| 2023 | 21.6 | -0.07 | 5.31 | 1.83 | - |
| 2024 | 13.4 | 0.40 | 4.04 | 1.46 | - |
| 2025 | 23.3 | -3.12 | 4.87 | 1.88 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-3.88 | $1.71M | $-94.18M | -5504.1% |
| 2017 | $-2.47 | $28.48M | $-74.87M | -262.9% |
| 2018 | $-1.19 | $280.41M | $-39.13M | -14% |
| 2019 | $-0.24 | $296.7M | $-8.15M | -2.7% |
| 2020 | $0.76 | $310.02M | $26.75M | 8.6% |
| 2021 | $1.86 | $276.87M | $71.52M | 25.8% |
| 2022 | $-0.74 | $463.93M | $-25M | -5.4% |
| 2023 | $1.29 | $566.77M | $48.16M | 8.5% |
| 2024 | $1.86 | $631.45M | $69.19M | 11% |
| 2025 | $1.73 | $780.57M | $62.87M | 8.1% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $8.05 | $7.70 – $8.28 | $809.53M | $806.78M – $812.29M | 3 |
| 2027 | $7.19 | $5.27 – $9.31 | $683.01M | $636.06M – $729.95M | 3 |
| 2028 | $7.10 | $6.42 – $7.87 | $662.95M | $614.3M – $718.11M | 1 |
| 2029 | $8.88 | $8.03 – $9.84 | $741.8M | $687.37M – $803.52M | 1 |
| 2030 | $9.39 | $8.49 – $10.40 | $767.9M | $711.55M – $831.79M | 1 |
